The Role of Stereotactic Body Radiotherapy in the Management of Non-small Cell Lung Cancer: an Emerging Standard for the Medically Inoperable Patient?

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2010 May 7

PMID 20446066

Citations 19

Authors

Gregory M M Videtic

Kevin L Stephans

Affiliations

Soon will be listed here.

Abstract

The standard of care for early-stage lung cancer is surgical resection. Many patients with this diagnosis have comorbidities that preclude oncologic resection. Randomized data show that limited resection is inadequate for local disease control and may negatively impact on survival. Stereotactic body radiotherapy (SBRT) has emerged as a novel radiation modality with significant applications in the inoperable, early-stage lung cancer population. Retrospective and prospective studies published in the past decade have established the feasibility, safety, and efficacy of SBRT in these patients using a variety of dose regimens and technologies. To date, lung SBRT results demonstrate excellent local control with very little acute toxicity, and suggest improved overall survival compared to historical controls of fractionated radiotherapy. Ongoing prospective trials are exploring dose and fractionation schedules in the inoperable population, and are starting to explore the role of SBRT for the operable patient.

Citing Articles

The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.

Buchberger D, Khurana R, Bolen M, Videtic G J Clin Med. 2025; 13(24.

PMID: 39768701 PMC: 11727850. DOI: 10.3390/jcm13247777.

SGRT-based stereotactic body radiotherapy for lung cancer setup accuracy and margin of the PTV.

Guo H, Wu W, Huan Y, Zhang H J Appl Clin Med Phys. 2023; 25(3):e14195.

PMID: 37915300 PMC: 10930008. DOI: 10.1002/acm2.14195.

Reproducibility of surface-based deep inspiration breath-hold technique for lung stereotactic body radiotherapy on a closed-bore gantry linac.

Nguyen D, Reinoso R, Farah J, Yossi S, Lorchel F, Passerat V Phys Imaging Radiat Oncol. 2023; 26:100448.

PMID: 37252251 PMC: 10213090. DOI: 10.1016/j.phro.2023.100448.

Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients.

Li F, Jiang H, Bu M, Mu X, Zhao H Radiat Oncol. 2022; 17(1):211.

PMID: 36564845 PMC: 9789627. DOI: 10.1186/s13014-022-02183-3.

Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Chen D, Zhao M, Xiang X, Liang J Chin Med J (Engl). 2022; .

PMID: 35830244 PMC: 9532043. DOI: 10.1097/CM9.0000000000002131.

References

Perez C, Pajak T, Rubin P, Simpson J, Mohiuddin M, BRADY L . Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987; 59(11):1874-81. DOI: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. View

Henderson M, Hoopes D, Fletcher J, Lin P, Tann M, Yiannoutsos C . A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 76(3):789-95. PMC: 2823932. DOI: 10.1016/j.ijrobp.2009.02.051. View

Jensik R, Faber L, MILLOY F, Monson D . Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973; 66(4):563-72. View

McKenna Jr R, Mahtabifard A, Yap J, McKenna 3rd R, Fuller C, Merhadi A . Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg. 2008; 85(2):S733-6. DOI: 10.1016/j.athoracsur.2007.11.049. View

Lax I, Blomgren H, Naslund I, Svanstrom R . Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 33(6):677-83. DOI: 10.3109/02841869409121782. View

Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M . Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2008; 74(1):47-54. DOI: 10.1016/j.ijrobp.2008.06.1939. View

Fakiris A, McGarry R, Yiannoutsos C, Papiez L, Williams M, Henderson M . Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75(3):677-82. DOI: 10.1016/j.ijrobp.2008.11.042. View

Stephans K, Djemil T, Reddy C, Gajdos S, Kolar M, Mason D . A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol. 2009; 4(8):976-82. DOI: 10.1097/JTO.0b013e3181adf509. View

Zierhut D, Bettscheider C, Schubert K, van Kampen M, Wannenmacher M . Radiation therapy of stage I and II non-small cell lung cancer (NSCLC). Lung Cancer. 2001; 34 Suppl 3:S39-43. DOI: 10.1016/s0169-5002(01)00381-6. View

10.

Sibley G . Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma: smaller volumes and higher doses--a review. Cancer. 1998; 82(3):433-8. View

11.

Wulf J, Baier K, Mueller G, Flentje M . Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005; 77(1):83-7. DOI: 10.1016/j.radonc.2005.09.003. View

12.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

13.

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T . Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63(5):1427-31. DOI: 10.1016/j.ijrobp.2005.05.034. View

14.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J . Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30):4833-9. DOI: 10.1200/JCO.2006.07.5937. View

15.

Shennib H, Bogart J, Herndon J, Kohman L, Keenan R, Green M . Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg. 2005; 129(4):813-8. DOI: 10.1016/j.jtcvs.2004.05.011. View

16.

Fowler J, Tome W, Fenwick J, Mehta M . A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004; 60(4):1241-56. DOI: 10.1016/j.ijrobp.2004.07.691. View

17.

Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H . Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2007; 70(4):1057-65. DOI: 10.1016/j.ijrobp.2007.07.2383. View

18.

Forquer J, Fakiris A, Timmerman R, Lo S, Perkins S, McGarry R . Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol. 2009; 93(3):408-13. DOI: 10.1016/j.radonc.2009.04.018. View

19.

Hoppe B, Laser B, Kowalski A, Fontenla S, Pena-Greenberg E, Yorke E . Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk?. Int J Radiat Oncol Biol Phys. 2008; 72(5):1283-6. DOI: 10.1016/j.ijrobp.2008.08.036. View

20.

Haasbeek C, Lagerwaard F, Antonisse M, Slotman B, Senan S . Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer. 2009; 116(2):406-14. DOI: 10.1002/cncr.24759. View